Global Stem Cell Therapy Market, by Cell Source (Adult Stem Cells, Induced Pluripotent Stem Cells, Embryonic Stem Cells, and Others), by Application (Musculoskeletal Disorders, Wounds and Injuries, Cancer, Autoimmune Disorders, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),
was valued at US$ 7,313.6
million in 2018, and is expected to exhibit a CAGR of 21.1%
over the forecast period (2019-2027), as highlighted in a new report published by .
Increasing application of stem cells for the treatment of patients with blood-related cancers, spinal cord injury and other diseases are the leading factors that are expected to drive growth of stem cell therapy market over the forecast period. According to the National Spinal Cord Injury Statistical Center, 2016, the annual incidence of spinal cord injury (SCI) is approximately 54 cases per million population in the U.S. or approximately 17,000 new SCI cases each year. Moreover, according to the Leukemia and Lymphoma Society, 2017, around 172,910 people in the U.S. were diagnosed with leukemia, lymphoma or myeloma in 2017, thus leading to increasing adoption of stem cells for its efficient treatment.
Increasing product launches by key players such as medium for developing embryonic stem cells is expected to propel the market growth over the forecast period. For instance, in January 2019, STEMCELL Technologies launched mTeSR Plus, a feeder-free human pluripotent stem cell (hPSC) maintenance medium for avoiding conditions associated with DNA damage, genomic instability, and growth arrest in hPSCs. With the launch of mTeSR, the company has expanded its portfolio of mediums for maintenance of human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells.
Increasing research and development of induced pluripotent stem cells coupled with clinical trials is expected to boost growth of the stem cell therapy market over the forecast period. For instance, in April 2019, Fate Therapeutics in collaboration with UC San Diego researchers launched Off-the-shelf immunotherapy (FT500) developed from human induced pluripotent stem cells. The therapy is currently undergoing clinical trials for the treatment of advanced solid tumors.
Browse 33 Market Data Tables and 21 Figures spread through 153 Pages and in-depth TOC on ‘Stem Cell Therapy Market’- Global Forecast to 2027, by Cell Source (Adult Stem Cells, Induced Pluripotent Stem Cells, Embryonic Stem Cells, and Others), by Application (Musculoskeletal Disorders, Wounds and Injuries, Cancer, Autoimmune Disorders, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),
To know the latest trends and insights prevalent in the Stem Cell Therapy Market, click the link below:
North America is expected to hold a dominant position in the stem cell therapy market over the forecast period, owing increasing number of clinical trials to cater to unmet medical needs of the patients is a major factor driving growth of the stem cell therapy market. For instance, in April, 2019, UCLA-UCI Alpha Stem Cell Clinic participated in a new clinical research study to investigate a stem cell product CTX0E03 DP, in order to improve function in people with chronic disability from ischemic stroke. The study, called PISCES III, is currently in phase IIb clinical study.
Moreover, manufacturers are focused on collaborating with academic researchers to help expand the potential use of newborn stem cell therapies that may be available to patients, which is expected to facilitate growth of the market over the forecast period. For instance, in February 2018, the Institute of Integrative Biology entered into a collaboration with Anika Therapeutics, Inc., to develop an injectable mesenchymal stem cell (MSC) therapy for the treatment of osteoarthritis in patients.
Key Takeaways of the Stem Cell Therapy Market:
- The global stem cell therapy market is expected to exhibit a CAGR of 21.1% over the forecast period, owing to increasing adoption of collaboration and acquisition strategies by market players and rising adoption of stem cell therapy in the market. For instance, in 2016, Axiogenesis AG and Metrion Biosciences Ltd. entered into a collaboration to validate, optimize, and commercialize induced pluripotent stem cell-derived cells and tissues, to speed up research in drug discovery
- Among cell source, adult stem cells segment held dominant position in the stem cell therapy market in 2018, owing to adoption of inorganic growth strategies such as partnerships and collaborations by the market players. For instance, in October 2016, Pall Corporation and RoosterBio Inc., an adult stem cell technology company, announced a co-development and marketing partnership. Under this partnership, the companies offered solutions for expansion of large-scale bioreactors of human mesenchymal stem/stromal cells (hMSCs) to accelerate product development and commercialization of stem cell based therapies in the market.
- Among region, North America segment held dominant position in the stem cell therapy market in 2018, owing to rising prevalence of cancer in the region that is expected to drive growth of the stem cell therapy market. For instance, according to a report by National Cancer Institute, in 2016, around 1,685,210 new cases of cancer were diagnosed in the U.S. alone.
- Key players operating in the global stem cell therapy market include Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Anterogen Co. Ltd., Pharmicell Co., Inc., and Stemedica Cell Technologies, Inc.